Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Berman Tabacco Announces Investigation of TransMedics Group, Inc. (TMDX) Concerning Claims by Scorpion Capital and Its FDA Citizen Petition

TMDX

Boston, Massachusetts--(Newsfile Corp. - January 15, 2025) - Berman Tabacco announces that it is investigating potential securities law violations by TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ: TMDX).

About the Investigation

On January 10, 2025, before the market open, Scorpion Capital announced on X that it was "short $TMDX TransMedics, " issued a reported titled "Walk Like An Egyptian: A 'Mafia-Style' Extortion, Racketeering, And Organ Trafficking Scheme Masquerading As A Medical Device Company – Fueled By Kickbacks, Billing Fraud, Unreported Device Failures, And Off-Label Misuse On A Vast Scale; Precipitating A Customer Exodus And Rapidly Unfolding Death Spiral" and stated that it planned to "shortly file a Citizen Petition with the FDA."

On January 13, 2025, before the market opened, TransMedics issued a press release stating, in part, "We strongly believe that the claims made in the Scorpion Capital report have no merits [sic], and were primarily intended to manipulate the market for financial gains."

On January 14, 2025, Scorpion Capital announced on X that it had "submitted a Citizen Petition with the FDA requesting suspension of Pre-Market Approval (PMA) for TransMedics OCS devices, particularly OCS Liver, which is the bulk of its usage."

Shares of TransMedics are down from a closing price of $72.55 per share on January 8, 2025 to a closing price of $62.54 on January 14, 2025, a decline of $10.01 or 13.8%.

Contact

If you have information concerning Scorpion Capital's report or would like more information about our investigation, please click here: Shareholder Contact | Berman Tabacco or contact us at 800-516-9926 or law@bermantabacco.com.

About Berman Tabacco

Since 1982, our firm has prosecuted hundreds of securities and antitrust complex cases. The firm and its attorneys have been recognized for their work on behalf of plaintiffs, including by Chambers USA, Benchmark Litigation, which has ranked the firm as Highly Recommended and a Top Ten Plaintiffs, The Legal 500, U.S. News & World Report-Best Lawyers, The Daily Journal, Lawdragon, Who's Who Legal, and Super Lawyers. The firm has offices in Boston, Massachusetts and San Francisco, California.

For more information, click here or contact us at 800-516-9926 or law@bermantabacco.com.

This notice may constitute attorney advertising.

Past results do not guarantee future outcomes.

Jay Eng, Esq.
Berman Tabacco
One Liberty Square
Boston, Massachusetts
(800) 516-9926
Email: law@bermantabacco.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/237332